OncLive, the official website for the Oncology Specialty Group, published a video on September 18, in which two researchers discuss the significant impact of ibrutinib on the WM community.
The IWMF is pleased to welcome two new members to its prestigious Scientific Advisory Committee (SAC) chaired by Dr. Robert Kyle of the Mayo Clinic.
The IWMF is aware that the potential cost of novel oral medications such as IMBRUVICA® (ibrutinib) is a recent and growing concern to the WM community.
On Wednesday, September 2nd, the IWMF partnered with the U.S.-based cancer support services organization, CancerCare, in a Connect Education Workshop on WM.
IWMF is partnering with the U.S.-based cancer support services organization, CancerCare, in a Connect Education Workshop on WM. On Wednesday, September 2nd, from 1:30 – 2:30PM
Dr. Robert Kyle, Professor of Medicine and Laboratory Medicine and Pathology at Mayo Clinic and noted international expert on WM, recently celebrated a landmark 52-year anniversary
AbbVie announced on July 10, 2015, that the European Commission has granted marketing authorization for Imbruvica (ibrutinib) for the treatment of Waldenstrom’s macroglobulinemia.
Select videos from the 2015 IWMF Educational Forum (held in Dallas, Texas, on May 1-3, 2015) are now available.
On May 16-17, a joint IWMF/LLS Strategic Research Roadmap Conference was held in New York City.
The Leukemia & Lymphoma Society (LLS) Telephone/Web Educational Program - Clinical Trials or Standard Treatment?